1st Counsel – Lifestyle
Author:
FLAGSHIP PIONEERING
Repertoire Immune Medicines Announces First Participant Dosed in Phase 1/2 Trial of RPTR-1-201, a T Cell-Targeted Immune Medicine for Advanced Solid Tumors
April 23, 2026
Flagship Pioneering Launches Serif Biomedicines to Establish Modified DNA as a New Biotechnology
April 21, 2026
Ampersand Biomedicines Presents Preclinical Data on AMP-220, a Gut-Targeted IL-22 AND-Body™ Therapeutic, at AAI 2026
April 20, 2026
Flagship Pioneering and AWS Announce Collaboration to Accelerate Drug Discovery and Life Sciences Innovation
April 1, 2026
Flagship Pioneering Appoints Eric Topol as Academic Advisor to Advance Preemptive Health and Medicine Initiative
March 17, 2026